Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma

Clinical and Vaccine Immunology

Volumn 21, Issue 2, 2014, Pages 256-259

  Lutzky, Viviana P ^a   Crooks, Pauline ^a   Morrison, Leanne ^a   Stevens, Natasha ^a   Davis, Joanne E ^a,b   Corban, Monika ^a   Hall, David ^c   Panizza, Benedict ^c   Coman, William B ^c   Coman, Scott ^c   Moss, Denis J ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG; MALE; NASOPHARYNGEAL NEOPLASMS; RECURRENCE; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS;

EID: 84893327408     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00121-13     Document Type: Article

References (18)

1. Lutzky VP, Davis JE, Crooks P, Corban M, Smith MC, Elliott M, Morrison L, Cross S, Tscharke D, Panizza B, Coman W, Bharadwaj M, Moss DJ. 2009. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients. Immunol. Cell Biol. 87:481-488. http://dx.doi.org/10.1038/icb. 2009.25.
2. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. 1997. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J. Immunol. 158:3325-3334. (Pubitemid 127484050)
3. Anagnostopoulos I, Hummel M. 1996. Epstein-Barr virus in tumours. Histopathology 29:297-315. http://dx.doi.org/10.1111/j.1365-2559.1996.tb01414.x. (Pubitemid 26338434)
4. Khanna R, Burrows SR. 2000. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54:19-48. http://dx.doi.org/10.1146/annurev.micro.54.1.19.
5. Haque T, Taylor C, Wilkie GM, Murad P, Amlot PL, Beath S, McKiernan PJ, Crawford DH. 2001. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 72:1399-1402. http://dx.doi.org/10.1097/00007890- 200110270-00012. (Pubitemid 33015766)
6. Rooney CM, Smith CA, Ng CYC, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. 1995. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9-13. http://dx.doi.org/10.1016/S0140-6736(95)91150-2.
7. Khanna R, Bell S, Sherritt M, Galbraith A, Burrows SR, Rafter L, Clarke B, Slaughter R, Falk MC, Douglas J, Willams T, Moss DJ. 1999. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. U. S. A. 96:10391-10396. http://dx.doi.org/10.1073/pnas.96.18. 10391. (Pubitemid 29422568)
8. Sherritt MA, Bharadwaj M, Burrows JM, Morrison LE, Elliott SL, Davis JE, Kear LM, Slaughter RE, Bell SC, Galbraith AJ, Khanna R, Moss DJ. 2003. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 75:1556-1560. http://dx.doi.org/10.1097/01.TP. 0000058745.02123.6F. (Pubitemid 36597295)
9. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, Gee AP, Russell HV, Brenner MK, Rooney CM, Heslop HE. 2005. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 105:1898-1904. http://dx.doi.org/10.1182/blood-2004-07-2975. (Pubitemid 40731770)
10. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S. 2005. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J. Clin. Oncol. 23:8942-8949. http://dx.doi.org/10.1200/JCO.2005.02.6195. (Pubitemid 46211479)
11. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, Kwong D, Khanna R. 2012. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 72:1116-1125. http://dx.doi.org/10.1158/0008-5472.CAN-11-3399.
12. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, Gee A, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. 2010. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J. Immunother. 33:983-990. http://dx.doi.org/10.1097/CJI.0b013e3181f3cbf4.
13. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ. 2008. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14:169-177. http://dx.doi.org/10.1158/1078-0432.CCR-07-1881.
14. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361:1838-1847. http://dx.doi.org/10.1056/NEJMoa0810097.
15. Hislop AD, Taylor GS, Sauce D, Rickinson AB. 2007. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu. Rev. Immunol. 25:587-617. http://dx.doi.org/10.1146/annurev.immunol.25.022106.141553. (Pubitemid 46697918)
16. Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. 2001. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res. 61:6219-6226. (Pubitemid 32762560)
17. Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP. 1999. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 59:5452-5455. (Pubitemid 29526455)
18. Lei KI, Chan LY, Chan WY, Johnson PJ, Lo YM. 2000. Quantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. Br. J. Haematol. 111:239-246. http://dx.doi.org/10.1046/j.1365-2141.2000.02344.x.